- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02358135
Collaborative Connected Health (CCH) for PCORI (PCORI)
Collaborative Connected Health (CCH): A Pragmatic Trial Evaluating Effectiveness of CCH in Psoriasis Management Compared to In-person Visits.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90089
- University of Southern California
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis School of Medicine
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Denver
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Be age 18 years and older
- Have physician-diagnosed plaque psoriasis
- Have access to internet and a digital camera or a mobile phone with camera features
- Have a primary care provider or the ability to establish primary care
Exclusion Criteria:
-
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Sonstiges: Control
In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services.
The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician.
In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face.
The patients in the in-person arm can seek psoriasis care from primary care practitioners or dermatologists, just as they would in the real world.
|
In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services.
The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician.
In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face.
The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
|
Experimental: CCH Model
The intervention arm will be the collaborative connected health (CCH) model, which purports to increase access to specialists and improve outcomes.
Specifically, CCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously.
CCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
|
CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments.
Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Improvement in Self-Administered Psoriasis Area and Severity Index (SA-PASI)
Zeitfenster: 12 months
|
Participants are asked to complete self-administered Psoriasis Area and Severity Index (SA-PASI).
SA-PASI combines the assessment of lesion severity (erythema, induration, and scale) and the affected areas into a single score between 0 (no disease) to 72 (maximal disease).
The primary outcome of the study was the mean percent improvement in SA-PASI averaged over three, six, nine, and 12 months.
The percent improvement in SA-PASI was defined as the difference in SA-PASI scores between the baseline and each of the follow-up visits divided by the SA-PASI score from the baseline visit.
|
12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Improvement in Quality of Life as Measured by Dermatology-Specific, Quality of Life Instruments
Zeitfenster: 12 months
|
Quality of life will be assessed using dermatology-specific, quality of life instruments, Skindex-16 and Dermatology Life Quality Index (DLQI). Scores for these assessments will be compared between patients randomized to the CCH model and in-person care. Skindex-16 is a validated and reliable instrument that comprehensively captures the effects of skin disease on health-related quality of life. It discriminates among patients with different effects and is responsive to clinical changes over time. Skindex-16 scores range from 0 (no effect) to 100 (effect experienced all the time), and the responses are aggregated in symptoms, emotions, and functioning subscales. The Dermatology Life Quality Index (DLQI) is another validated dermatology-specific quality-of-life instrument that has been used in many psoriasis trials. DLQI scores range from 0 to 30, with higher scores indicating more severe impact on quality of life. |
12 months
|
Access to Care: Distance Traveled
Zeitfenster: 12 months.
|
Access to care is an overall term to capture the transportation to care factors including total distance traveled to see a provider (round-trip driving distance from patient's home to provider's office multiplied by the number of in-person visits during the study period).
|
12 months.
|
Depression Severity
Zeitfenster: 12 months
|
Participants will be assessed for depression severity using the Patient Health Questionnaire (PHQ), a validated, self-administered diagnostic instrument for common mental disorders. The PHQ-9 score can range from 0 to 27 with 0 = "No" depression and 27 = "Severe" depression. The PHQ is a validated, self-administered version of the Primary Care Evaluation of Mental Disorders (PRIME-MD) diagnostic instrument for common mental disorders. The PHQ-9 is the depression module, which scores each of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) depression criteria as "0" (not at all) to "3" (nearly every day). A PHQ-9 score of 10 or greater has 89% sensitivity and 88% specificity for major depression. PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. PHQ-9 is a validated tool for diagnosis of depression and monitoring response to interventions. |
12 months
|
Other Psoriasis Disease Severity Measures
Zeitfenster: 12 months
|
Body surface area (BSA) involvement and patient global assessment (PtGA) will be compared between the patients randomized to the CCH model and the in-person care. The BSA assessment is a well-established, validated measure used by psoriasis patients to report percent body surface affected by psoriasis in numerous prior studies. BSA ranges from 0% (no involvement) to 100% (complete body surface affected). The PtGA is a validated instrument that measures the overall psoriasis severity from the patients' perspective.40 PtGA is an ordinal six-point scale ranging from 0 (clear) to 5 (severe). |
12 months
|
Access to Care: Wait Time
Zeitfenster: 12 months
|
Access to care is an overall term to capture transportation factors including time taken to be seen by a provider.
me.
Wait time is measured by calculating roundtrip transportation time plus in-office waiting time multiplied by the number of in-person visits during the study period.
|
12 months
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: April Armstrong, MD MPH, University of Southern California
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Armstrong AW, Chambers CJ, Maverakis E, Cheng MY, Dunnick CA, Chren MM, Gelfand JM, Wong DJ, Gibbons BM, Gibbons CM, Torres J, Steel AC, Wang EA, Clark CM, Singh S, Kornmehl HA, Wilken R, Florek AG, Ford AR, Ma C, Ehsani-Chimeh N, Boddu S, Fujita M, Young PM, Rivas-Sanchez C, Cornejo BI, Serna LC, Carlson ER, Lane CJ. Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial. JAMA Netw Open. 2018 Oct 5;1(6):e183062. doi: 10.1001/jamanetworkopen.2018.3062.
- Armstrong AW, Ford AR, Chambers CJ, Maverakis E, Dunnick CA, Chren MM, Gelfand JM, Gibbons CM, Gibbons BM, Lane CJ. Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial. J Invest Dermatol. 2019 May;139(5):1037-1044. doi: 10.1016/j.jid.2018.09.039. Epub 2018 Nov 24.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HS-15-00417
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Schuppenflechte
-
ProgenaBiomeRekrutierungSchuppenflechte | Psoriasis vulgaris | Psoriasis der Kopfhaut | Psoriasis-Plaque | Psoriasis universalis | Psoriasis-Gesicht | Psoriasis-Nagel | Psoriasis diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis anularis | Psoriasis genital | Psoriasis GeographicaVereinigte Staaten
-
Clin4allRekrutierungPsoriasis der Kopfhaut | Psoriasis-Nagel | Psoriasis Palmaris | Psoriasis genital | Psoriasis plantarisFrankreich
-
Centre of Evidence of the French Society of DermatologyRekrutierungSchuppenflechte | Psoriasis vulgaris | Psoriasis der Kopfhaut | Psoriasis-Plaque | Psoriasis universalis | Psoriasis Palmaris | Psoriatische Erythrodermie | Psoriasis-Nagel | Psoriasis Guttat | Psoriasis umgekehrt | Psoriasis pustulöseFrankreich
-
Innovaderm Research Inc.AbgeschlossenPsoriasis der Kopfhaut | Pustulöse palmo-plantare Psoriasis | Nicht pustulöse Palmo-plantare Psoriasis | Ellenbogen-Psoriasis | Unterschenkel-PsoriasisKanada
-
UCB Biopharma S.P.R.L.AbgeschlossenMittelschwere bis schwere Psoriasis | Generalisierte pustulöse Psoriasis und erythrodermische PsoriasisJapan
-
Herlev and Gentofte HospitalRekrutierungHerzinfarkt | Myokardischämie | Herzkrankheiten | Herz-Kreislauf-Erkrankungen | Herzfehler | Streicheln | Schuppenflechte | Herzinsuffizienz, diastolisch | Psoriasis vulgaris | Herz-Kreislauf-Risikofaktor | Herzinsuffizienz, systolisch | Linksventrikuläre Dysfunktion | Psoriasis universalis | Psoriasis-Gesicht | Psoriasis... und andere BedingungenDänemark
-
AmgenAbgeschlossenPsoriasis-Typ Psoriasis | Psoriasis vom Plaque-TypVereinigte Staaten
-
PfizerAbgeschlossenPsoriasis vulgaris | Pustulöse Psoriasis | Psoriasis Arthropathica | Erythrodermische PsoriasisJapan
-
TakedaRekrutierungGeneralisierte pustulöse Psoriasis | Erythrodermische PsoriasisJapan
-
Janssen Pharmaceutical K.K.RekrutierungGeneralisierte pustulöse Psoriasis | Erythrodermische PsoriasisJapan
Klinische Studien zur Control
-
Indiana UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...RekrutierungEmpfängnisverhütung | Nutzung des Gesundheitswesens | Verwendung von VerhütungsmittelnVereinigte Staaten
-
Cairo UniversityNoch keine Rekrutierung
-
Northwestern UniversityAbgeschlossen
-
Evidence-Based Practice Institute, Seattle, WANational Institute of Mental Health (NIMH); University of MarylandNoch keine RekrutierungVerhaltensstörungen bei Kindern | Selbstmord und SelbstverletzungVereinigte Staaten
-
University of Southern MississippiMilitary Suicide Research ConsortiumAnmeldung auf EinladungSuizidgedanken | AngstempfindlichkeitVereinigte Staaten
-
Rethink Medical SLRekrutierungLebensqualität | Katheterbedingte Komplikationen | Katheterassoziierte HarnwegsinfektionSpanien
-
Rethink Medical SLZurückgezogenHarnverhalt | Katheterkomplikationen | Katheterassoziierte HarnwegsinfektionSpanien
-
Argosy UniversityAbgeschlossenPosttraumatische BelastungsstörungVereinigte Staaten
-
W.L.Gore & AssociatesAbgeschlossenThoraxerkrankungenSchweden, Niederlande, Spanien, Deutschland, Frankreich, Vereinigtes Königreich, Italien
-
Ryerson UniversityAbgeschlossen